Merck Serono presents positive trial data for MS drug
19 April 2010 00:00 in Pharmaceutical Company Product News
Merck Serono has published data from a phase III clinical trial underlining the efficacy of its multiple sclerosis (MS) drug cladribine.
According to the results of the Clarity trial, patients using Merck Serono's drug saw a statistically significant increase in health benefits when compared to a placebo control group.
These included a decrease in the number of relapses, as well as a reduction in their dependence on societal support and healthcare resources.
Bernhard Kirschbaum, Merck Serono's head of global research and development, said the analysis underlines the "relevance" of this latest trial of its investigational oral treatment.
He added: "We are committed to continuing to work with regulatory authorities to bring cladribine tablets to patients at the earliest point in time."
This data was revealed by Merck Serono at the 62nd Annual Meeting of the American Academy of Neurology, where the company also presented new data on the long-term efficacy of its established MS treatment Rebif.
Other news stories from 19/04/2010
Related news
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency
